{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:04:57Z","timestamp":1784948697110,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41375-024-02147-4","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T14:02:32Z","timestamp":1706018552000},"page":"424-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-7078","authenticated-orcid":false,"given":"Harpreet K.","family":"Mandhair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Radpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Westerhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-0297","authenticated-orcid":false,"given":"Magali","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Arambasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Dengjel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-3647","authenticated-orcid":false,"given":"Mario P.","family":"Tschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2147_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell Lymphoma. N. Engl J Med. 2021;384:842\u201358.","journal-title":"N. Engl J Med"},{"key":"2147_CR2","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2147_CR3","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"2147_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature"},{"key":"2147_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","volume":"130","author":"T Erdmann","year":"2017","unstructured":"Erdmann T, Klener P, Lynch JT, Grau M, Vo\u010dkov\u00e1 P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310\u201322.","journal-title":"Blood"},{"key":"2147_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/15548627.2016.1140293","volume":"12","author":"JM Park","year":"2016","unstructured":"Park JM, Jung CH, Seo M, Otto NM, Grunwald D, Kim KH, et al. The ULK1 complex mediates MTORC1 signaling to the autophagy initiation machinery via binding and phosphorylating ATG14. Autophagy. 2016;12:547\u201364.","journal-title":"Autophagy"},{"key":"2147_CR7","doi-asserted-by":"publisher","first-page":"eabd5016","DOI":"10.1126\/scitranslmed.abd5016","volume":"13","author":"A Ianniciello","year":"2021","unstructured":"Ianniciello A, Zarou MM, Rattigan KM, Scott M, Dawson A, Dunn K, et al. ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. Sci Transl Med. 2021;13:eabd5016.","journal-title":"Sci Transl Med"},{"key":"2147_CR8","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.4081\/ejh.2015.2481","volume":"59","author":"AM Schl\u00e4fli","year":"2015","unstructured":"Schl\u00e4fli AM, Berezowska S, Adams O, Langer R, Tschan MP. Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur J Histochem. 2015;59:2481.","journal-title":"Eur J Histochem"},{"key":"2147_CR9","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","volume":"34","author":"GA Horne","year":"2020","unstructured":"Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, et al. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020;34:1775\u201386.","journal-title":"Leukemia"},{"key":"2147_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/gcc.10025","volume":"33","author":"S Mehra","year":"2002","unstructured":"Mehra S, Messner H, Minden M, Chaganti RS. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer. 2002;33:225\u201334.","journal-title":"Genes Chromosomes Cancer"},{"key":"2147_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm2199","volume":"8","author":"D Ron","year":"2007","unstructured":"Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007;8:519\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2147_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257\u201364.","journal-title":"Blood"},{"key":"2147_CR13","doi-asserted-by":"publisher","first-page":"E7260","DOI":"10.1073\/pnas.1610970113","volume":"113","author":"L Rui","year":"2016","unstructured":"Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2016;113:E7260\u2013e7267.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2147_CR14","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701\u201313.","journal-title":"Blood"},{"key":"2147_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649\u201362.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02147-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:07:20Z","timestamp":1707131240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02147-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andrew Davies: <i>Celgene (a Bristol Myers Squibb company):<\/i> Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Travel to scientific conferences, Research Funding; <i>Roche:<\/i> Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Research support. Travel to scientific conferences, Research Funding; <i>Kite, a Gilead company:<\/i> Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Research support; <i>GSK:<\/i> Other: Research support; <i>Ascerta Pharma\/Astra Zeneca:<\/i> Honoraria, Other: Research support; <i>Incyte:<\/i> Membership on an entity\u2019s Board of Directors or advisory committees; <i>Abbvie:<\/i> Membership on an entity\u2019s Board of Directors or advisory committees; <i>Takeda:<\/i> Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Research support. Urban Novak: reports consulting fees and advisory board participation to\/through the institution from and with Janssen-Cilag, Celgene (BMS), Takeda, AstraZeneca, Roche, Novartis, Incyte, Beigene, Kyowa Kirin, Gilead, Pierre Fabre and Miltenyi, payment of honoraria to the institution form Celgene (BMS), Novartis, Takeda, and Gilead, and meeting and\/or travel support to the institution from Janssen, Roche, Gilead, and Takeda. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}